Literature DB >> 20832008

Dose-response relationship for lung cancer induction at radiotherapy dose.

Uwe Schneider1, Andrea Stipper, Jürgen Besserer.   

Abstract

Cancer induction after radiation therapy is a severe side effect. It is therefore of interest to predict the probability of second cancer appearance for the treated patient. Currently there is large uncertainty about the shape of the dose-response relationship for carcinogenesis for most cancer types at high dose levels. In this work a dose-response relationship for lung cancer is derived based on (i) the analysis of lung cancer induction after Hodgkin's disease, (ii) a cancer risk model developed for high doses including fractionation based on the linear quadratic model, and (iii) the reconstruction of treatment plans for Hodgkin's patients treated with radiotherapy. The fitted model parameters for an α/β=3 Gy were α=0.061Gy(-1) and R=0.84. The value for α is in agreement with analysis of normal tissue complications of the lung after radiation therapy. The repopulation/repair parameter R is large, but seems to be characteristic for lung tissue which is sensitive with regard to fractionation. Lung cancer risk is according to this model for small doses consistent with the finding of the A-bomb survivors, has a maximum at doses of around 15 Gy and drops off only slightly at larger doses. The predicted EAR for lung after radiotherapy of Hodgkin's disease is 18.4/10000PY which can be compared to the findings of several epidemiological studies were EAR for lung varies between 9.7 and 21.5/10000PY.
Copyright © 2010. Published by Elsevier GmbH.

Entities:  

Mesh:

Year:  2010        PMID: 20832008     DOI: 10.1016/j.zemedi.2010.03.008

Source DB:  PubMed          Journal:  Z Med Phys        ISSN: 0939-3889            Impact factor:   4.820


  8 in total

1.  Assessment of uncertainties in radiation-induced cancer risk predictions at clinically relevant doses.

Authors:  J Nguyen; M Moteabbed; H Paganetti
Journal:  Med Phys       Date:  2015-01       Impact factor: 4.071

2.  Dose-response relationship for breast cancer induction at radiotherapy dose.

Authors:  Uwe Schneider; Marcin Sumila; Judith Robotka; Günther Gruber; Andreas Mack; Jürgen Besserer
Journal:  Radiat Oncol       Date:  2011-06-08       Impact factor: 3.481

3.  Site-specific dose-response relationships for cancer induction from the combined Japanese A-bomb and Hodgkin cohorts for doses relevant to radiotherapy.

Authors:  Uwe Schneider; Marcin Sumila; Judith Robotka
Journal:  Theor Biol Med Model       Date:  2011-07-26       Impact factor: 2.432

Review 4.  Important determinants for fucoidan bioactivity: a critical review of structure-function relations and extraction methods for fucose-containing sulfated polysaccharides from brown seaweeds.

Authors:  Marcel Tutor Ale; Jørn D Mikkelsen; Anne S Meyer
Journal:  Mar Drugs       Date:  2011-10-24       Impact factor: 6.085

5.  Modeling the risk of secondary malignancies after radiotherapy.

Authors:  Uwe Schneider
Journal:  Genes (Basel)       Date:  2011-11-29       Impact factor: 4.096

6.  Late radiation toxicity in Hodgkin lymphoma patients: proton therapy's potential.

Authors:  Allison Toltz; Naomi Shin; Ellis Mitrou; Cecile Laude; Carolyn R Freeman; Jan Seuntjens; William Parker; David Roberge
Journal:  J Appl Clin Med Phys       Date:  2015-09-08       Impact factor: 2.102

7.  Anatomy-dependent lung doses from 3D-conformal breast-cancer radiotherapy.

Authors:  Pavel Kundrát; Hannes Rennau; Julia Remmele; Sabine Sebb; Cristoforo Simonetto; Jan Christian Kaiser; Guido Hildebrandt; Ulrich Wolf; Markus Eidemüller
Journal:  Sci Rep       Date:  2022-06-28       Impact factor: 4.996

8.  Radiation-induced second malignancies after involved-node radiotherapy with deep-inspiration breath-hold technique for early stage Hodgkin Lymphoma: a dosimetric study.

Authors:  Uwe Schneider; Marcin Sumila; Judith Robotka; Damien Weber; Günther Gruber
Journal:  Radiat Oncol       Date:  2014-02-18       Impact factor: 3.481

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.